bevacizumab + carboplatin + paclitaxel + parsatuzumab

This is a combination regimen consisting of four agents: - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby restricting tumor blood supply. - **Carboplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Paclitaxel** is a taxane-class chemotherapeutic that stabilizes microtubules, preventing cell division. - **Parsatuzumab** appears to be an erroneous or unrecognized name; no evidence exists for an approved or investigational drug by this name. It may be a typographical error for "pertuzumab" or "trastuzumab," both HER2-targeted monoclonal antibodies used in breast cancer regimens with the other listed drugs[1][2][3]. Combination regimens similar to this (with trastuzumab instead of parsatuzumab) are used as neoadjuvant therapy for HER2-positive breast cancer, leveraging antiangiogenic and cytotoxic mechanisms alongside HER2 inhibition[1][3]. The addition of bevacizumab has been studied but raises concerns about wound healing and cardiac toxicity[1].